American Century Companies Inc. Increases Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

American Century Companies Inc. lifted its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 1.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 1,092,754 shares of the company’s stock after purchasing an additional 13,046 shares during the period. American Century Companies Inc. owned about 0.82% of Centessa Pharmaceuticals worth $15,714,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in CNTA. Janus Henderson Group PLC grew its holdings in shares of Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after purchasing an additional 3,614,623 shares during the last quarter. Foresite Capital Management VI LLC bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at $20,994,000. Point72 Asset Management L.P. raised its holdings in Centessa Pharmaceuticals by 26.2% during the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock valued at $57,396,000 after buying an additional 710,936 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Centessa Pharmaceuticals by 14.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock valued at $89,854,000 after buying an additional 685,371 shares during the last quarter. Finally, Farallon Capital Management LLC raised its holdings in Centessa Pharmaceuticals by 24.3% during the 4th quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company’s stock valued at $58,603,000 after buying an additional 684,391 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CNTA. Wall Street Zen lowered shares of Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a “buy” rating and a $35.00 price target for the company. Truist Financial began coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They set a “buy” rating and a $30.00 price target for the company. Finally, Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 price objective for the company. Eleven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $28.10.

Centessa Pharmaceuticals Stock Down 3.0%

Shares of NASDAQ CNTA opened at $17.01 on Monday. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $9.60 and a 12 month high of $19.09. The firm has a market capitalization of $2.28 billion, a PE ratio of -9.50 and a beta of 1.48. The firm has a fifty day simple moving average of $15.28 and a two-hundred day simple moving average of $14.49.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Equities analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $15.56, for a total value of $155,600.00. Following the sale, the insider directly owned 122,279 shares of the company’s stock, valued at $1,902,661.24. This represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mario Alberto Accardi sold 8,322 shares of the company’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $15.23, for a total transaction of $126,744.06. Following the completion of the sale, the insider directly owned 208,163 shares in the company, valued at $3,170,322.49. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 181,322 shares of company stock valued at $2,601,014 over the last 90 days. 7.09% of the stock is owned by corporate insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.